Lupin's Famotidine for Oral Suspension receives FDA approval

Jul 2 2010

Lupin Pharmaceuticals, Inc. (LPI) announced today that it has received final approval from the US Food and Drug Administration (FDA) for its Famotidine for Oral Suspension (40 mg / 5 mL).  Commercial shipments of the product have already commenced.

Lupin's Famotidine for Oral Suspension is the AB-rated generic equivalent of Merck's PEPCID® indicated for the short-term treatment of active duodenal ulcer, active benign gastric ulcer, and gastroesophageal reflux disease (GERD).    PEPCID for Oral Suspension had annual sales of approximately $29 million for the twelve months ended March 2010, based on IMS Health sales data.

SOURCE Lupin Pharmaceuticals, Inc.